Prospective Observational Study to Monitor and Assess the Safety of Amvuttra® [Vutrisiran] in a Real-World Cohort of hATTR Amyloidosis Patients

First published: 22/01/2024 Last updated: 07/05/2025





Administrative details

EU PAS number	
EUPAS108904	
Study ID	
199013	
DARWIN EU® study	
No	
Study countries	
☐ Brazil	
Bulgaria	
Denmark	

France
Germany
☐ Israel
Italy
Netherlands
Portugal
Spain
Taiwan
United Kingdom
United States
Study description
This is a multinational, non-interventional, observational study based on
secondary use of data and conducted over a period of 10 years to evaluate the
safety of vutrisiran in hATTR amyloidosis participants exposed to vutrisiran
under real-world conditions.
Study status
Study status
Ongoing
Research institutions and networks
Institutions
United BioSource Corporation (UBC)
Switzerland
First published: 25/04/2013
First published: 25/04/2013
Last updated: 06/03/2024



Multiple centres: 41 centres involved in the study

Contact details

Study institution contact

Karien Verhulst kverhulst@alnylam.com

Study contact

kverhulst@alnylam.com

Primary lead investigator

Emily Brouwer

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 29/02/2024

Study start date

Planned: 29/02/2024

Actual: 10/04/2024

Date of final study report

Planned: 31/12/2034

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Alnylam

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Main study objective:

Primary aim = long-term(>2 years) safety of vutrisiran under real-world conditions including determining & comparing incidence of selected events of interest (clinical consequences of vitamin A deficiency, including delayed symptoms &hypersensitivity reactions) in hATTR amyloidosis participants exposed to vutrisiran as compared to other medications (except patisiran) treating hATTR amyloidosis.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name

AMVUTTRA

Study drug International non-proprietary name (INN) or common name

VUTRISIRAN

Anatomical Therapeutic Chemical (ATC) code

(N07XX18) vutrisiran

vutrisiran

Medical condition to be studied

Acquired ATTR amyloidosis

Additional medical condition(s)

Transthyretin-mediated amyloidosis, Hereditary transthyretin-mediated amyloidosis

Population studied

Short description of the study population

Not yet known, study will enroll hATTR patients, who will be treated per standard of care.

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Special population of interest

Hepatic impaired

Pregnant women

Estimated number of subjects

300

Study design details

Outcomes

1. Number of Participants With Adverse Events (AEs) due toClinical Consequences of Vitamin A Deficiency, IncludingDelayed Symptoms

2. Number of Participants With AEs due to HypersensitivityReactions, Number of Hepatic AEs in Participants With Moderate/Severe Hepatic Impairment; Pregnancy Outcomes (Live/Preterm Births, Spontaneous Abortions, Stillbirths & Elective/Therapeutic Abortions); Infant Outcomes, Congenital Malformations at Birth & Lactation & Infant Follow-up Data Through First Year of Life; Epidemiological & Clinical Characteristics of Patients Treated With Vutrisiran in Real-world

Data analysis plan

Descriptive statistics for continuous variables including the number of observations, mean, standard deviation, median, interquartile range, and minimum/maximum; the associated 95% confidence interval (CI) will be provided, as appropriate.

Categorical variables will be summarised as frequency and proportion of the relevant population.

Summary statistics will be presented for the full study population and separately by subgroups (eg, exposure status, liver transplant status, hepatic impairment status, occurrence of specified safety events of interest) where appropriate.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (type: Other)
Data sources (type Prospective patient-b	
Use of a Com	mon Data Model (CDM)
CDM mapping No	
Data quality s	pecifications
Check conformance	
Unknown	
Check completenes	5
Unknown	
Check stability	

Data characterisation

Data characterisation conducted

No